申请人:Takeda Pharmaceutical Company Limited
公开号:EP1876179A1
公开(公告)日:2008-01-09
The present invention relates to a compound represented by the formula:
wherein
Ar is an optionally substituted ring;
A is a spacer having a main chain of 1 to 4 atoms;
B is a bond, a C1-10 alkylene group or an oxygen atom;
R3 and R5 are each independently a hydrogen atom or a substituent;
R4 is an optionally substituted cyclic group or an optionally substituted C1-10 alkyl group; and
R1 and R2 are each independently a hydrogen atom or a substituent, or
R1 and R2 or R1 and B are bonded to form an optionally substituted nitrogen-containing heterocycle, or
R1 and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.
本发明涉及一种由式表示的化合物:
其中
Ar 是任选取代的环;
A 是具有 1 至 4 个原子主链的间隔物
B 是键、C1-10 亚烷基或氧原子;
R3 和 R5 各自独立地为氢原子或取代基;
R4 是任选取代的环状基团或任选取代的 C1-10 烷基;以及
R1 和 R2 各自独立地为氢原子或取代基,或
R1 和 R2 或 R1 和 B 键合形成任选取代的含氮杂环,或
R1 和 Ar 键合形成任选取代的含氮融合杂环或其盐。本发明的噻吩嘧啶酮化合物具有优异的黑色素浓缩激素受体拮抗作用,可用作预防或治疗肥胖症等的药物。